AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21569282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention arms.
Number of subjects: 1731
Study 18177789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 34
Study 18177789 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually randomized trials
Number of subjects: 34
Study 18177789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials (adjusted for clustering)
Number of subjects: 34
Study 18177789 — intervention group
Group type: COMPARATOR
Intervention: Baseline imbalances in cluster randomized studies
Number of subjects: 34
Study 18177789 — intervention group
Group type: COMPARATOR
Intervention: Baseline imbalances in individually randomized studies
Number of subjects: 34
Study 17135806 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated CGIC
Number of subjects: 650
Study 17135806 — intervention group
Group type: EXPERIMENTAL
Intervention: Study partner-rated CGIC
Number of subjects: 650
Study 17135806 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of subject ratings with partner ratings
Number of subjects: 650
Study 17135806 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change over 3 months
Number of subjects: 650
Study 17135806 — intervention group
Group type: COMPARATOR
Intervention: Home-based vs clinic-based ratings
Number of subjects: 650
Study 17135806 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations with change scores of selected clinical rating scales
Number of subjects: 650
Study 12548295 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g/day of berries (black currants, lingonberries and bilberries) for 8 weeks
Number of subjects: 40
Study 12548295 — intervention group
Group type: COMPARATOR
Intervention: Habitual Finnish diets (control group)
Number of subjects: 40
Study 10702460 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg. kg(‐1). h(‐1) dexmedetomidine
Number of subjects: 7
Study 10702460 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 microg. kg(‐1). h(‐1) dexmedetomidine
Number of subjects: 7
Study 10702460 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study 9196412 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 22
Study 9196412 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 22
Study 8403586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release flurbiprofen 200 mg
Number of subjects: 24
Study 2906886 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg acrivastine given three times daily
Number of subjects: 49
Study 2906886 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine given three times daily
Number of subjects: 49
Study 2906886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg clemastine given three times daily
Number of subjects: 49
Study 2906886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31425456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Exercise (HI)
Number of subjects: 30
Study 31425456 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume Resistance Exercise (HV)
Number of subjects: 30
Study 31425456 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 30040140 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity Fracture Liaison Service (active-control)
Number of subjects: 361
Study 30040140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity Fracture Liaison Service (case manager)
Number of subjects: 361
Study 27029362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium exposure group
Number of subjects: 298
Study 25322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low maintain dose (0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 120
Study 25322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high maintain dose (0.7 microg x kg(‐1) x h(‐1))
Number of subjects: 120
Study 25322607 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 120
Study 23692634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategy to support full clinical pathway implementation for asthma.
Number of subjects: 16
Study 23692634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategy to support full clinical pathway implementation for gastroenteritis.
Number of subjects: 16
Study 23692634 — intervention group
Group type: COMPARATOR
Intervention: Control group for asthma pathway implementation.
Number of subjects: 16
Study 23692634 — intervention group
Group type: COMPARATOR
Intervention: Control group for gastroenteritis pathway implementation.
Number of subjects: 16
Study 20484548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3264
Study 20484548 — intervention group
Group type: COMPARATOR
Intervention: Zinc (10 mg)
Number of subjects: 3264
Study 20484548 — intervention group
Group type: COMPARATOR
Intervention: Iron + Folic Acid (12.5 mg iron + 50 microg folic acid)
Number of subjects: 3264
Study 20484548 — intervention group
Group type: COMPARATOR
Intervention: Zinc + Iron + Folic Acid (10 mg zinc + 12.5 mg iron + 50 microg folic acid)
Number of subjects: 3264
Study 17593932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn berries
Number of subjects: 254
Study 17593932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 16720676 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP II™ index
Number of subjects: 42
Study 16720676 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS XP™ index
Number of subjects: 42
Study 14572943 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentations about nicotine replacement treatment (NRT)
Number of subjects: 504
Study 10470219 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IL-2 (high-dose)
Number of subjects: 116
Study 7567847 — intervention group
Group type: EXPERIMENTAL
Intervention: Three million units of alpha‐lymphoblastoid interferon (n = 30)
Number of subjects: 85
Study 7567847 — intervention group
Group type: EXPERIMENTAL
Intervention: Six million units of alpha‐lymphoblastoid interferon (n = 30)
Number of subjects: 85
Study 7567847 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group, n = 25)
Number of subjects: 85
Study 1770153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of alprazolam
Number of subjects: 125
Study 1770153 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 125
Study 1770153 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 7015093 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin (Hoe 069 + depot component)
Number of subjects: 100
Study 28513897 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct light-activated composite resin restorations
Number of subjects: 138
Study 28674922 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary contractions (VOL group)
Number of subjects: 36
Study 28674922 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-induced contractions (NMES group)
Number of subjects: 36
Study 28674922 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study 25848210 — intervention group
Group type: COMPARATOR
Intervention: HX‐1171, single ascending doses of 20, 40, 80, 160, 300, 600, 1,200, 1,500 or 2,000 mg administered to 67 subjects.
Number of subjects: 83
Study 25848210 — intervention group
Group type: COMPARATOR
Intervention: HX‐1171, multiple ascending doses of 500 or 1,000 mg administered to 16 subjects for 14 days.
Number of subjects: 83
Study 25848210 — intervention group
Group type: COMPARATOR
Intervention: HX‐1171, single and multiple doses.
Number of subjects: 83
Study 24384083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (no NR)
Number of subjects: 21
Study 24384083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (mild NR)
Number of subjects: 21
Study 24384083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS (maximum NR)
Number of subjects: 21
Study 24384083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem 16 BICROS
Number of subjects: 21
Study 24384083 — intervention group
Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 21
Study 21084767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride treatment
Number of subjects: 16
Study 21084767 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate treatment
Number of subjects: 16
Study 21084767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride treatment (PEPT2*2/*2)
Number of subjects: 16
Study 21084767 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate treatment (PEPT2*1/*1)
Number of subjects: 16
Study 19861194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (IT group)
Number of subjects: 63
Study 19861194 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (oral group)
Number of subjects: 63
Study 17978987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of denicotinized cigarettes (Quest 3) and 21‐mg nicotine patch for 2 weeks before the quit date
Number of subjects: 98
Study 17978987 — intervention group
Group type: COMPARATOR
Intervention: Light cigarettes (Quest 1) during the 2 weeks before the quit date
Number of subjects: 98
Study 15195985 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training (HT) - twice‐daily functional balance and strength exercises and 3 group meetings
Number of subjects: 77
Study 15195985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT) - group training twice weekly and the same home exercises
Number of subjects: 77
Study 15195985 — intervention group
Group type: COMPARATOR
Intervention: Home training (HT)
Number of subjects: 77
Study 15195985 — intervention group
Group type: COMPARATOR
Intervention: Combined training (CT)
Number of subjects: 77
Study 11706532 — intervention group
Group type: EXPERIMENTAL
Intervention: CR10 Borg's scale
Number of subjects: 15
Study 11706532 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS (visual analogue scale)
Number of subjects: 15
Study 9152568 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg SR morphine sulfate capsule administered while fasting
Number of subjects: 24
Study 9152568 — intervention group
Group type: COMPARATOR
Intervention: 20-mg SR morphine sulfate capsule administered after a high-fat meal
Number of subjects: 24
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 4 weeks
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 2 weeks
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 4 weeks
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg every 2 weeks
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic scores
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary calcium/creatinine and hydroxyproline/creatinine ratios
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone alkaline phosphatase concentrations
Number of subjects: 61
Study 7525038 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic changes
Number of subjects: 61
Study 3496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid hygiene only
Number of subjects: 128
Study 3496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (25 mg/kg twice daily for 14 days)
Number of subjects: 128
Study 3496872 — intervention group
Group type: COMPARATOR
Intervention: Topical chloramphenicol
Number of subjects: 128
Study 3496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe conjunctivitis treatment
Number of subjects: 128
Study 3496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystitis
Number of subjects: 128
Study 3496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonchlamydial conjunctivitis
Number of subjects: 128
Study 29945711 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg vaginally daily from 22+0 to 24+0 weeks until 34+0 weeks' gestation
Number of subjects: 1197
Study 29945711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study 28347354 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients
Number of subjects: 19
Study 28347354 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinician recruiters
Number of subjects: 19
Study 26441180 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal resection (n=238)
Number of subjects: 475
Study 26441180 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy and rectal resection (n=237)
Number of subjects: 475
Study 22697581 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged healing (AuS)
Number of subjects: 52
Study 22697581 — intervention group
Group type: COMPARATOR
Intervention: Non-submerged healing (AuNS)
Number of subjects: 52
Study 20951235 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy for PTSD delivered via telehealth technology
Number of subjects: 0
Study 20951235 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based therapy for PTSD delivered in-person
Number of subjects: 0
Study 18468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 400mg, three times daily for 12 weeks
Number of subjects: 78
Study 18468736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 78
Study 18468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 78
Study 17178264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 441
Study 17178264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 441
Study 17178264 — intervention group
Group type: COMPARATOR
Intervention: Gln27 (Control)
Number of subjects: 441
Study 17178264 — intervention group
Group type: COMPARATOR
Intervention: Glu27 (Control)
Number of subjects: 441
Study 12812863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management training
Number of subjects: 48
Study 12812863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 10897742 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural and relational techniques (sophrology, maintenance of the help relation, visualization-relaxation)
Number of subjects: 0
Study 8866928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine (50 mg in 4 ml saline)
Number of subjects: 0
Study 8866928 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (10 mg solution)
Number of subjects: 0
Study 8866928 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (5 mg)
Number of subjects: 0
Study 1704212 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 554
Study 1704212 — intervention group
Group type: EXPERIMENTAL
Intervention: Loculated fluid pattern recognition
Number of subjects: 554
Study 6403140 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer supplementation (Caloreen) at 6 g/kg body weight daily
Number of subjects: 14
Study 6403140 — intervention group
Group type: COMPARATOR
Intervention: Normal feeding
Number of subjects: 14
Study 29466076 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 43
Study 29466076 — intervention group
Group type: COMPARATOR
Intervention: No taping (control)
Number of subjects: 43
Study 29506460 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT group (spot serum procalcitonin guided protocol)
Number of subjects: 50
Study 29506460 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (antibiotics stopped according to physicians' discretion)
Number of subjects: 50
Study 29506460 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT group
Number of subjects: 50
Study 29506460 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 50
Study 27423790 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Problem Analysis of Raising Kids
Number of subjects: 4438
Study 27423790 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without structured interview)
Number of subjects: 4438
Study 25074713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal scarification (1 ml normal saline injection)
Number of subjects: 291
Study 25074713 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg intramuscular injection)
Number of subjects: 291
Study 23130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (1.5 oz/day of walnuts, 6 times/week)
Number of subjects: 25
Study 23130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (8 oz/week of salmon)
Number of subjects: 25
Study 23130505 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25
Study 23130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 25
Study 20148782 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced web-based intervention condition
Number of subjects: 2523
Study 20148782 — intervention group
Group type: COMPARATOR
Intervention: Basic information-only control condition
Number of subjects: 2523
Study 18981503 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN4Delta30-200,201 vaccine (10^5 PFU)
Number of subjects: 28
Study 18981503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15645213 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple semitendinosus tendon (ST) autografts
Number of subjects: 41
Study 15645213 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon (PT) autografts
Number of subjects: 41
Study 15645213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 12030916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 microg/kg i.v. at 0 min)
Number of subjects: 7
Study 12030916 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1.0 microm/kg i.v. at 0 min)
Number of subjects: 7
Study 12030916 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (SS, 2.0 microg/kg/h from -30 to +90 min)
Number of subjects: 7
Study 9825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg single oral dose)
Number of subjects: 240
Study 9825368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 240
Study 7644369 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-bubble method
Number of subjects: 0
Study 7644369 — intervention group
Group type: COMPARATOR
Intervention: Z-track method
Number of subjects: 0
Study 2664816 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (1 g amoxycillin/200 mg clavulanic acid, 3 to 4 intravenous doses per day for mean 7.7 days, followed by 500 mg amoxycillin/125 mg clavulanic acid, 4 to 6 tablets per day for mean 11.2 days)
Number of subjects: 152
Study 2664816 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (3 to 4 g amoxycillin or ampicillin, 160 mg gentamicin, and 1.5 g metronidazole, parenteral therapy for mean 7.7 days, followed by 2 to 3 g amoxycillin or ampicillin and 1 to 1.5 g metronidazole daily for mean 11.1 days)
Number of subjects: 152
Study 1145988 — intervention group
Group type: EXPERIMENTAL
Intervention: NISR 440 Polycarbonate Membrane
Number of subjects: 6
Study 1145988 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan
Number of subjects: 6
Study 31385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline plus magnesium (1000 mg choline bitartrate and 500 mg magnesium oxide)
Number of subjects: 96
Study 31385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (500 mg magnesium oxide)
Number of subjects: 96
Study 31385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline (1000 mg choline bitartrate)
Number of subjects: 96
Study 31385202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29904752 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA-free 1-step self-etch adhesive (1SEa G-Bond)
Number of subjects: 52
Study 29904752 — intervention group
Group type: COMPARATOR
Intervention: 3-step etch-and-rinse adhesive (3E&Ra Optibond FL)
Number of subjects: 52
Study 27217412 — intervention group
Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile)
Number of subjects: 3310
Study 27217412 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate hypertension control
Number of subjects: 3310
Study 27217412 — intervention group
Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile) and inadequate hypertension control
Number of subjects: 3310
Study 27217412 — intervention group
Group type: EXPERIMENTAL
Intervention: High baPWV (highest quartile) with adequate hypertension control
Number of subjects: 3310
Study 27217412 — intervention group
Group type: COMPARATOR
Intervention: Adequate hypertension control
Number of subjects: 3310
Study 25578330 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with glycopyrronium containing regimen
Number of subjects: 6000
Study 25578330 — intervention group
Group type: COMPARATOR
Intervention: Standard care without glycopyrronium
Number of subjects: 6000
Study 23473348 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 874
Study 23473348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 20040338 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg single oral dose
Number of subjects: 28
Study 20040338 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 28
Study 17976224 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (25 microg)
Number of subjects: 20
Study 17976224 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerine
Number of subjects: 20
Study 16620263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (202.65 kPa for 90 min, 5 days a week for 4 weeks)
Number of subjects: 38
Study 16620263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 38
Study 16620263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyperbaric therapy)
Number of subjects: 38